Market Cap
$2.2B
GPCR
Structure Therapeutics Inc.
$27.67 ▼ -4.52%
Prev close $28.98Market cap$2.2B
ConsensusStrong Buy
12-mo target$105.78 (+282.3%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)21 New Institutional Positions16 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on GPCR right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (91%)
Inst. Holders
50 funds
Inst. Value
$2.5B
Inst. Activity
21 buys / 16 sells
Insider Activity
$0.00 buy / $3.5M sell
Insider Net $
-$3.5M
Social Sentiment
50° Neutral
SEC Reports
4
Press Releases
2
Price chart 30d -41.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 25, 2026 short_volume
Short Volume: GPCR — 79.4% short (0.7M / 0.9M)
Short: 707,494 | Exempt: 0 | TRF Vol: 891,110 | Short Ratio: 79.4% | Off-exchange volume (dark pool
Sep 21, 2026 Insider
Coll Crespo Blas disposed of 12,024 shares
CHIEF MEDICAL OFFICER
Sep 21, 2026 Insider
Coll Crespo Blas acquired 4,008 shares
CHIEF MEDICAL OFFICER
Sep 21, 2026 Insider
Coll Crespo Blas sold 4,008 shares
CHIEF MEDICAL OFFICER @ $36.15 ($144.9K)
Jun 30, 2026 Inst.
RTW INVESTMENTS, LP — NEW
1,607,507 shares ($86.3M)
Jun 30, 2026 Inst.
Jun 11, 2026 SEC Aberdeen Group plc — ADD
639,915 shares ($34.3M)
A mixed institutional cluster in GPCR (2025-Q3) shows 4 buyers adding a net $6.0M against 3 sellers reducing by $51.6M.
INST-CLUSTER — Impact 5/10
Structure Therapeutics reported Q1 2026 net loss of $76.0M, widening from $46.8M a year ago, while announcing positive P
8-K — Impact 6/10
Analyst ratings buy % -4.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
91% rate it Buy or better · 23 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 9, 2026 | Citizens | REITERATE | Market Outperform | 38% |
| Aug 7, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Aug 7, 2026 | Citizens | MAINTAIN | Market Outperform | 38% |
| Jun 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Apr 27, 2026 | Canaccord Genuity | INITIATE | Buy | 47% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 8 | 13 | 2 | 0 | 0 | 91% | |
| Aug 1, 2026 | 8 | 13 | 2 | 0 | 0 | 91% | |
| Jul 1, 2026 | 8 | 14 | 2 | 0 | 0 | 92% | |
| Jun 1, 2026 | 8 | 14 | 2 | 0 | 0 | 92% | |
| May 1, 2026 | 8 | 14 | 2 | 0 | 0 | 92% | |
| Apr 1, 2026 | 8 | 13 | 2 | 0 | 0 | 91% | |
| Mar 1, 2026 | 8 | 13 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 8 | 13 | 1 | 0 | 0 | 95% |
Price targets
Where 15 covering analysts think GPCR trades over the next 12 months.
$105.78 +282.3% upside Strong Buy
Current$27.67 Low$70.00 Median$101.00 High$145.00 15 analysts
$70.00$145.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 0 bullish, 1 bearish, 2 mixed, 1 neutral · avg impact 5.0/10.Plus 2 press releases.
BEARISHINST-CLUSTER5/10
A mixed institutional cluster in GPCR (2025-Q3) shows 4 buyers adding a net $6.0M against 3 sellers
Jun 11, 2026
MIXED8-K6/10
Structure Therapeutics reported Q1 2026 net loss of $76.0M, widening from $46.8M a year ago, while a
May 7, 2026
NEUTRAL8-K3/10
Structure Therapeutics appointed Matthew Lang as Chief Operating Officer and General Counsel, effect
Apr 15, 2026
MIXEDINST-CLUSTER6/10
In Q4 2025, three mega-passive institutions—Fidelity, Morgan Stanley, and BofA—significantly increas
Feb 28, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 25, 2026
short_volume
Short Volume: GPCR — 79.4% short (0.7M / 0.9M)
Short: 707,494 | Exempt: 0 | TRF Vol: 891,110 | Short Ratio: 79.4% | Off-exchange volume (dark pool + OTC)
Sep 9, 2026
short_volume
Short Volume: GPCR — 65.1% short (0.4M / 0.6M)
Short: 412,876 | Exempt: 20,115 | TRF Vol: 634,191 | Short Ratio: 65.1% | Off-exchange volume (dark pool + OTC)
Sep 3, 2026
other
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Structure Therapeutics Participates in Upcoming Investor Conferences
Aug 4, 2026
earnings_calendar
GPCR Q2 2026 Earnings After Market Close — 2026-08-04
Jun 30, 2026
short_volume
Short Volume: GPCR — 66.1% short (0.4M / 0.6M)
Short: 382,890 | Exempt: 357 | TRF Vol: 579,262 | Short Ratio: 66.1% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.24 | $-0.57–$2.02 | 34.9% | -3.4% | 1↑ 6↓ | $0.1B | 10 |
| Next Q | $-0.49 | $-0.59–$-0.28 | -345.0% | -0.2% | 2↑ 5↓ | $0.0B | 10 |
| Current FY | $-1.61 | $-2.04–$0.94 | -100.8% | +0.9% | 0↑ 9↓ | $0.0B | 10 |
| Next FY | $-2.14 | $-2.47–$-1.57 | -33.4% | +2.0% | 1↑ 7↓ | $0.0B | 8 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.241 | — |
| 7d ago | $-0.233 | -0.008 |
| 30d ago | $-0.233 | -0.008 |
| 60d ago | $-0.187 | -0.054 |
| 90d ago | $-0.187 | -0.054 |
Institutional ownership
Which big funds own GPCR (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $2.5B total value (46,659,983 shares) as of 2026-Q2. Top holders: FMR, WELLINGTON, Avoro. Net buying activity: 21 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 7,810,306 | $419.2M | 16.8% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 7,379,433 | $396.1M | 15.8% | — |
| Avoro Capital Advisors LLC | 6,555,555 | $351.8M | 14.1% | — |
| Jupiter Topco LLC | 5,204,212 | $279.3M | 11.2% | — |
| MORGAN STANLEY | 2,806,640 | $150.6M | 6.0% | — |
| PRINCIPAL FINANCIAL GROUP INC | 1,752,753 | $94.1M | 3.8% | ADD +36.6% |
| AMERICAN CENTURY COMPANIES INC | 1,682,179 | $90.3M | 3.6% | DOUBLED +183.7% |
| RTW INVESTMENTS, LP | 1,607,507 | $86.3M | 3.4% | NEW |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1,553,219 | $83.4M | 3.3% | — |
| BAKER BROS. ADVISORS LP | 1,432,529 | $76.9M | 3.1% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | NEW | — | 1,607,507 | — | $86.3M |
| Aberdeen Group plc | ADD | 391,809 | 639,915 | +63.3% | $34.3M |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 227,132 | 563,422 | +148.1% | $30.2M |
| UBS Group AG | ADD | 212,919 | 378,986 | +78.0% | $20.3M |
| MARSHALL WACE, LLP | DOUBLED | 69,107 | 267,592 | +287.2% | $14.4M |
| NATIONAL BANK OF CANADA /FI/ | TRIM | 305,400 | 215,800 | -29.3% | $11.6M |
| Squarepoint Ops LLC | DOUBLED | 22,646 | 125,575 | +454.5% | $6.7M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | 55,842 | 122,344 | +119.1% | $6.6M |
| D. E. Shaw & Co., Inc. | TRIM | 204,790 | 115,300 | -43.7% | $6.2M |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | TRIM | 254,969 | 112,300 | -56.0% | $6.0M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
14 insiders, 50 transactions. Net -$3.5M — $0.00 bought, $3.5M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | CONVERT | 12,024 | — | — |
| Sep 21, 2026 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | CONVERT | 4,008 | — | — |
| Sep 21, 2026 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | SELL | 4,008 | $36.15 | $144.9K |
| Sep 18, 2026 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | TAX W/H | 10,626 | $11.67 | $124.0K |
| Sep 1, 2026 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | SELL | 100 | $47.83 | $4.8K |
| Sep 1, 2026 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | SELL | 1,300 | $45.86 | $59.6K |
| Sep 1, 2026 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | SELL | 4,539 | $47.20 | $214.3K |
| Sep 1, 2026 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | CONVERT | 17,817 | — | — |
| Sep 1, 2026 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | EXERCISE | 17,817 | $0.3400 | $6.1K |
| Sep 1, 2026 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | CONVERT | 5,939 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for GPCR.
Shares short
6,605,011
Settlement Sep 15, 2026
Change vs prior
+12.8%
Semi-monthly cycle
Days to cover
5.2
At avg daily volume
Of shares outstanding
≈9.3%
Estimate — not % of float
All GPCR filing & press-release reports (6)
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 7, 2026
- PRESS-RELEASE reportApr 27, 2026
- 8-K reportApr 15, 2026
- PRESS-RELEASE reportMar 16, 2026
- INST-CLUSTER reportFeb 28, 2026